← Compound index
COMPOUND RECORD / OGP

Osteogenic growth peptideОстеогенный ростовой пептид

Osteogenic growth peptide (OGP) is a 14-amino-acid peptide derived from the C-terminal sequence of histone H4. Bone studies distinguish full-length OGP from its shorter active fragment.

Source linked

What the studies found

Animal research · 2026

OGP-mimetic hydrogel promoted dental-tissue differentiation in experimental models

Dental-pulp differentiation
RUNX2, ALP and DSPP expression increasedHuman cells in culture
Cell proliferation
No significant change
Mineralized tissue
Increased formation in an ectopic renal-capsule modelEngineered hydrogel; not isolated OGP in patients

An engineered OGP-mimetic hydrogel enhanced osteogenic/odontogenic differentiation markers RUNX2, ALP and DSPP in dental-pulp stem cells, without significantly changing proliferation. It also increased mineralized-tissue formation in an ectopic implantation model. The system was designed to protect its peptide cargo and control release.

Study notes · methods, sources and limitations

Participants or model Human dental-pulp stem-cell cultures and an ectopic renal-capsule implantation model; OGP-mimetic hydrogel.

Important limitations

  • The intervention is an engineered OGP-fragment-mimetic hydrogel, not unmodified OGP. Human cells in culture are not treated patients; the implantation model is not a clinical dental-pulp trial.

Biomaterials 338(Pt B) · Journal publication

Original source or citation ↗

Study results and tables ↗

Computer modeling · 2026

OGP informs a CB2-binding model and design of a different candidate peptide

Screening
56 peptides → 5 candidates
Pep-5 functional potency
EC50 6.0 micromolarPep-5 cell assay; NOT an OGP potency estimate
OGP contribution
Modeled CB2 allosteric bindingDocking and molecular dynamics, not a clinical experiment

OGP and Pepcan-12 were used to model a proposed allosteric binding site on CB2. Screening 56 peptides yielded five candidates. Pep-5, the best-performing new candidate, inhibited cAMP accumulation with an EC50 of 6.0 micromolar and enhanced the effect of WIN55,212-2 in the cell assay.

Study notes · methods, sources and limitations

Participants or model CB2 receptor docking and molecular dynamics; cell-based functional testing of a newly designed peptide, Pep-5.

Important limitations

  • The measured 6.0 micromolar potency belongs to Pep-5, not OGP. OGP binding was computationally modeled. The proposed binding site and new candidate do not establish a treatment effect in people.

Bioorganic & medicinal chemistry 143 · Journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 1992

Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity.

Synthetic 14-amino-acid OGP increased osteoblast proliferation and alkaline-phosphatase activity in culture and increased bone mass in injected rats.

Study notes · methods, sources and limitations

Participants or model Osteoblast cultures and rats

Important limitations

  • Preclinical endpoints do not establish fracture prevention or benefit in people. The full-length peptide must be distinguished from its 10–14 fragment and tissue mixtures.

EMBO Journal. 11(5):1867–1873 · Indexed abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Osteogenic growth peptide

Names in this research collection

OGP · OGP(10–14)

Identity / background source ↗

Research background

An international peptide-research comparator with original osteoblast and rodent studies. Full-length OGP, its active fragment and marrow extracts are distinct research preparations.

Compound class
Archival preparation lead
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

No treatment trial in the newly recovered sources

Study methods

Animal and cell experiments; observational serum data

Independent replication

Related reports are not automatically independent evidence

Source access

Original indexed abstracts; full methodological appraisal pending

Safety evidence

Clinical safety, product equivalence and interactions not established by this collection

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The available experimental studies leave human benefit and safety uncertain.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Computer modeling · 2026

Targeting the putative allosteric site J of cannabinoid receptor type 2 with peptide modulators: From mechanistic investigation to candidate identification

OGP and Pepcan-12 were used to model a proposed allosteric binding site on CB2. Screening 56 peptides yielded five candidates. Pep-5, the best-performing new candidate, inhibited cAMP accumulation with an EC50 of 6.0 micromolar and enhanced the effect of WIN55,212-2 in the cell assay.

Study notes and original source
2026Computational mechanism studyEnglish abstract

Targeting the putative allosteric site J of cannabinoid receptor type 2 with peptide modulators: From mechanistic investigation to candidate identification

· Journal publication

Zhang X, Chen Z, Su M · Bioorganic & medicinal chemistry 143

OGP and Pepcan-12 were used to model a proposed allosteric binding site on CB2. Screening 56 peptides yielded five candidates. Pep-5, the best-performing new candidate, inhibited cAMP accumulation with an EC50 of 6.0 micromolar and enhanced the effect of WIN55,212-2 in the cell assay.

Results and tables

Reported findings and study design

OGP and Pepcan-12 were used to model a proposed allosteric binding site on CB2. Screening 56 peptides yielded five candidates. Pep-5, the best-performing new candidate, inhibited cAMP accumulation with an EC50 of 6.0 micromolar and enhanced the effect of WIN55,212-2 in the cell assay.

Population or model CB2 receptor docking and molecular dynamics; cell-based functional testing of a newly designed peptide, Pep-5.

Results · Indexed abstract checked
MeasureResultComparison, timing and statistics
Screening56 peptides → 5 candidates
Pep-5 functional potencyEC50 6.0 micromolarPep-5 cell assay; NOT an OGP potency estimate
OGP contributionModeled CB2 allosteric bindingDocking and molecular dynamics, not a clinical experiment

The measured 6.0 micromolar potency belongs to Pep-5, not OGP. OGP binding was computationally modeled. The proposed binding site and new candidate do not establish a treatment effect in people.

Source for these results ↗ · Reviewed 2026-10-31

Population / setting
CB2 receptor docking and molecular dynamics; cell-based functional testing of a newly designed peptide, Pep-5.
Source reviewed
Primary publication metadata and indexed abstract checked through Europe PMC on 31 October 2026. No unavailable effect sizes inferred.
Study limitations
  • The measured 6.0 micromolar potency belongs to Pep-5, not OGP. OGP binding was computationally modeled. The proposed binding site and new candidate do not establish a treatment effect in people.

Reviewed 2026-10-31.

Read the source ↗

Animal research · 2026

An OGP binding protein complex-mimicking peptide hydrogel for dental pulp regeneration

An engineered OGP-mimetic hydrogel enhanced osteogenic/odontogenic differentiation markers RUNX2, ALP and DSPP in dental-pulp stem cells, without significantly changing proliferation. It also increased mineralized-tissue formation in an ectopic implantation model. The system was designed to protect its peptide cargo and control release.

Study notes and original source
2026Animal / experimentalEnglish abstract

An OGP binding protein complex-mimicking peptide hydrogel for dental pulp regeneration

· Journal publication

Sha Y, Zhan W, Qin Z, Sun S, Li J, Zong Y, Li M, Jiang F, Liang G, Zhang G · Biomaterials 338(Pt B)

An engineered OGP-mimetic hydrogel enhanced osteogenic/odontogenic differentiation markers RUNX2, ALP and DSPP in dental-pulp stem cells, without significantly changing proliferation. It also increased mineralized-tissue formation in an ectopic implantation model. The system was designed to protect its peptide cargo and control release.

Results and tables

Reported findings and study design

An engineered OGP-mimetic hydrogel enhanced osteogenic/odontogenic differentiation markers RUNX2, ALP and DSPP in dental-pulp stem cells, without significantly changing proliferation. It also increased mineralized-tissue formation in an ectopic implantation model. The system was designed to protect its peptide cargo and control release.

Population or model Human dental-pulp stem-cell cultures and an ectopic renal-capsule implantation model; OGP-mimetic hydrogel.

Results · Indexed abstract checked
MeasureResultComparison, timing and statistics
Dental-pulp differentiationRUNX2, ALP and DSPP expression increasedHuman cells in culture
Cell proliferationNo significant change
Mineralized tissueIncreased formation in an ectopic renal-capsule modelEngineered hydrogel; not isolated OGP in patients

The intervention is an engineered OGP-fragment-mimetic hydrogel, not unmodified OGP. Human cells in culture are not treated patients; the implantation model is not a clinical dental-pulp trial.

Source for these results ↗ · Reviewed 2026-10-31

Population / setting
Human dental-pulp stem-cell cultures and an ectopic renal-capsule implantation model; OGP-mimetic hydrogel.
Source reviewed
Primary publication metadata and indexed abstract checked through Europe PMC on 31 October 2026. No unavailable effect sizes inferred.
Study limitations
  • The intervention is an engineered OGP-fragment-mimetic hydrogel, not unmodified OGP. Human cells in culture are not treated patients; the implantation model is not a clinical dental-pulp trial.

Reviewed 2026-10-31.

Read the source ↗

Animal research · 1992

Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity.

Synthetic 14-amino-acid OGP increased osteoblast proliferation and alkaline-phosphatase activity in culture and increased bone mass in injected rats.

Study notes and original source
1992Animal / experimentalEnglish abstract

Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity.

14-amino-acid OGP; not a marrow extract

Format: Journal article · Reviewed: Indexed abstract reviewed

I. Bab, D. Gazit, M. Chorev, A. Muhlrad, A. Shteyer, Z. Greenberg, M. Namdar, A. Kahn · EMBO Journal. 11(5):1867–1873

Synthetic 14-amino-acid OGP increased osteoblast proliferation and alkaline-phosphatase activity in culture and increased bone mass in injected rats.

Population / setting
Osteoblast cultures and rats
Source reviewed
Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Study limitations
  • Preclinical endpoints do not establish fracture prevention or benefit in people.
  • The full-length peptide must be distinguished from its 10–14 fragment and tissue mixtures.

Reviewed 2026-10-03.

Read the source ↗

Animal research · 2022

Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2.

The authors reported bone and inflammatory effects that disappeared after genetic or pharmacological disruption of CB2. Circulating OGP declined with age in the women sampled; this was not a treatment trial.

Study notes and original source
2022Animal / experimentalEnglish abstract

Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2.

OGP experimental preparations; sequence-specific methods require full-text appraisal

Format: Journal article · Reviewed: Indexed abstract reviewed

B. Raphael-Mizrahi, M. Attar-Namdar, M. Chourasia, M. G. Cascio, Y. Gabet, et al. · eLife. 11:e65834

The authors reported bone and inflammatory effects that disappeared after genetic or pharmacological disruption of CB2. Circulating OGP declined with age in the women sampled; this was not a treatment trial.

Population / setting
Mouse models, cell assays including human osteoblasts, and observational human serum measurements
Source reviewed
Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Study limitations
  • Mouse treatment and cultured human cells do not demonstrate human treatment efficacy.
  • The human serum association cannot establish causation.
  • Full-length OGP and the active fragment must be distinguished in each experimental method.

Reviewed 2026-10-03.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗